ENDRA Life Sciences, Inc. recently announced a partnership with Shanghai General Hospital in China.
The collaboration will be the first clinical study of ENDRA’s Thermo Acoustic Enhanced Ultrasound (TAEUS®) device to assess Non-Alcoholic Fatty Liver Disease (NAFLD), according to a Jan. 24 press release.
“ENDRA is honored to bring our TAEUS® technology to China through one of the country’s most prestigious healthcare institutions, Shanghai General,” ENDRA CEO Francois Michelon said in the release. “This partnership is a clear validation of ENDRA’s technology and provides an important strategic entry point into China’s healthcare market, which seeks to deliver cost-effective health services to 1.4 billion citizens including an estimated 350 million people affected by NAFLD-NASH (Nonalcoholic Steatohepatitis). We believe ENDRA’s point-of-care TAEUS® technology aligns very well with China’s goal of shifting the delivery of healthcare services from urban centers to community clinics.”
The study will compare ENDRA’s TAEUS® liver device against a baseline measure of liver fat in 75 patients and evaluate the design and performance of the product, the release stated.
Vice Chairman of the Chinese Society of Hepatology, Professor Lu Lungen, said he is excited about the partnership.
“We are committed to maintaining a first-class modern hospital that is research-driven and provides low-cost, high-efficiency clinical care," Lungen said in the release. "We look forward to using ENDRA’s TAEUS® technology with our NAFLD patients as a promising alternative to more invasive or costly techniques."
Shanghai General is a Class A tertiary general hospital that was founded in 1864 and remains one of the largest hospitals in China, according to the release.